Prof. Dr Mohammad Amjad Kamal is a distinguished scientist
affiliated with King Faisal
University, etc., where he leads a global research team.
His extensive contributions to biochemistry research have resulted in over 750
publications in internationally renowned journals and 65 abstracts presented at
international conferences. Notably, his work was pivotal in developing novel
anti-Alzheimer agents, transitioning them from the laboratory to clinical
trials in collaboration with Dr Nigel H. Greig, Chief of the Laboratory of
Neurosciences at the National Institutes of Health (NIH), USA. In 1998, Prof.
Kamal migrated to Australia and was awarded the prestigious U2000 Postdoctoral
Fellowship by the University of Sydney, School of Molecular and Microbial
Biosciences in 2000. This highly competitive three-year fellowship funded his
research on the “Inhibition of amido phosphoribosyl transferase by new
antifolates: Design and mechanism of action of purine antagonists.” He also
collaborated on a molecular biology research project addressing Type 2 diabetes
and Alzheimer’s disease at the University of Technology Sydney. He has been recognised
as a highly cited top 1% researcher in the last 3 consecutive years by
Clarivate (https://www.webofscience.com/wos/author/record/J-2918-2014).
Prof. Dr Mohammad Amjad Kamal is a distinguished scientist
affiliated with King Faisal
University, etc., where he leads a global research team.
His extensive contributions to biochemistry research have resulted in over 750
publications in internationally renowned journals and 65 abstracts presented at
international conferences. Notably, his work was pivotal in developing novel
anti-Alzheimer agents, transitioning them from the laboratory to clinical
trials in collaboration with Dr Nigel H. Greig, Chief of the Laboratory of
Neurosciences at the National Institutes of Health (NIH), USA. In 1998, Prof.
Kamal migrated to Australia and was awarded the prestigious U2000 Postdoctoral
Fellowship by the University of Sydney, School of Molecular and Microbial
Biosciences in 2000. This highly competitive three-year fellowship funded his
research on the “Inhibition of amido phosphoribosyl transferase by new
antifolates: Design and mechanism of action of purine antagonists.” He also
collaborated on a molecular biology research project addressing Type 2 diabetes
and Alzheimer’s disease at the University of Technology Sydney. He has been recognised
as a highly cited top 1% researcher in the last 3 consecutive years by
Clarivate (https://www.webofscience.com/wos/author/record/J-2918-2014).